title: The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors.
abstract: Occurrence of phenotypic abnormalities in CD34(+) hematopoietic progenitor and precursor cells (HPC) and their major B-cell and nonlymphoid compartments has been frequently reported in myelodysplastic syndromes (MDS). Here, we analyze for the first time the numerical and phenotypic abnormalities of different maturation-associated subsets of bone marrow (BM) CD34(+) HPC from 50 newly diagnosed MDS patients in comparison to normal/reactive BM (n=29). Our results confirm the existence of heterogeneously altered phenotypes among CD34(+) HPC from MDS and indicate that such variability depends both on the relative distribution of the different subsets of CD34(+) HPC committed into the different myeloid and B-lymphoid compartments, and their immunophenotype (for example, higher reactivity for CD117 and CD13 and lower expression of CyMPO, CD64 and CD65 on CD34(+) immature and neutrophil precursors), a clear association existing between the accumulation of CD34(+) HPC and that of immature CD34(+) HPC. Interestingly, expansion of erythroid- and neutrophil-lineage CD34(+) cells is detected in low-grade MDS at the expense of CD34(+) plasmacytoid dendritic cell and B-cell precursors, while expansion of immature CD34(+) precursors occurs in high-grade MDS. On the basis of the number and severity of the phenotypic abnormalities detected, a scoring system is proposed that efficiently discriminates between normal/reactive and MDS CD34(+) HPC, the mean score significantly increasing from low- to high-grade MDS.
authors.affiliation: Servicio General de Citometría, Departamento de Medicina, Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Universidad de Salamanca, Salamanca, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Matarraz
authors.forename: A
authors.initials: A
authors.lastname: López
authors.forename: S
authors.initials: S
authors.lastname: Barrena
authors.forename: C
authors.initials: C
authors.lastname: Fernandez
authors.forename: E
authors.initials: E
authors.lastname: Jensen
authors.forename: J
authors.initials: J
authors.lastname: Flores
authors.forename: P
authors.initials: P
authors.lastname: Bárcena
authors.forename: A
authors.initials: A
authors.lastname: Rasillo
authors.forename: J M
authors.initials: JM
authors.lastname: Sayagues
authors.forename: M L
authors.initials: ML
authors.lastname: Sánchez
authors.forename: P
authors.initials: P
authors.lastname: Hernandez-Campo
authors.forename: J M
authors.initials: JM
authors.lastname: Hernandez Rivas
authors.forename: C
authors.initials: C
authors.lastname: Salvador
authors.forename: N
authors.initials: N
authors.lastname: Fernandez-Mosteirín
authors.forename: M
authors.initials: M
authors.lastname: Giralt
authors.forename: L
authors.initials: L
authors.lastname: Perdiguer
authors.forename: A
authors.initials: A
authors.lastname: Orfao
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018952:Antigens, CD34 / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D001853:Bone Marrow / Q000473:pathology; D019070:Cell Lineage; D005260:Female; D005434:Flow Cytometry; D006412:Hematopoietic Stem Cells / Q000276:immunology*; D006801:Humans; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000276:immunology*; D023461:Myeloid Progenitor Cells / Q000276:immunology*; D009504:Neutrophils / Q000276:immunology / Q000378:metabolism; D011379:Prognosis
chemical_list: D018952:Antigens, CD34